ABOUT APPMED™

Powering
Precision Medecine with Live Clinical Patient Monitoring.

At the heart of everything we build is a single conviction: patients deserve treatment decisions grounded in their data, not population averages. AppMed™ exists to make that possible, at scale, at every step of care.

OUR MISSION

Empower. Optimize. Advance.

Our mission is to empower healthcare professionals with a digital platform designed to optimize drug dosage treatment, improve drug monitoring and communication amongst all stakeholders — ultimately enhancing clinical efficacy, driving better health outcomes, streamlining workflows, and advancing personalized medicine while fostering active patient and caregiver engagement in the treatment journey.

OUR VISION

Intelligence-Led. Patient-First.

Our vision is to transform healthcare by leveraging intelligent, data-driven, and patient-centric solutions to enhance personalized medicine and optimize treatment decisions. We envision a world where every clinical decision — from dosing to intervention — is supported by continuous, objective, real-time data from the individual patient.

OUR VALUES

What Guides Every Decision We Make

Four values that define how we work, how we build, and how we show up, for our patients, our partners, and one another.

Rigor

Through a culture of scientific and intellectual rigor, we are committed to empowering individuals to achieve excellence with persistent effort and critical thinking while upholding the highest standards of integrity and accountability. Every model, every alert, every clinical output meets a standard of defensible evidence.

Patient Centricity

Through collaboration, compassion, and innovation, we are dedicated to improving health outcomes and enhancing the overall patient experience. Our commitment to patient centricity drives us to create a supportive environment where patients feel empowered to take an active role in their healthcare journey.

Communityship

It takes a village to raise a child. We believe our employees are members of the healthcare community, and all shall take responsibility for that community’s growth and development while nurturing positive relationships. We recognize individuals’ different strengths and aim to combine them to make a productive team.

Actualization

We get things done and we build momentum to remain at the forefront of innovation — always looking for opportunities to create and improve. Speed and efficiency are the foundational elements of what we aim to accomplish, without ever compromising on the rigor that defines our work.

The Team

Built by Leaders Across Medecine, Law,
Engineering
and Finance

A multidisciplinary founding team with deep roots in clinical research, regulatory affairs, software engineering, and healthcare finance, united by a shared belief in the power of data-driven medicine.

MN
Martin Noël, PhD, MHA
CHIEF EXECUTIVE OFFICER
Accomplished leader with global expertise in medical affairs, drug development, clinical research, and commercialization across oncology, cardiology, gene therapy, and infectious diseases. Proven success in business development, regulatory negotiation, and market access.
DM
Danièle Milette, M.Fisc
Senior Financial Officer
Seasoned tax professional with extensive experience leading professional firms, specializing in technology companies. Provides strategic and financial guidance to start-ups, holds positions on multiple boards, and is an active investor within the Anges Québec network.
JCM
Jean-Charles Marin, CD, MBA, PhD
Senior Opperation Director
Strong knowledge in strategic management, performance frameworks, statistics, and operational research. Brings disciplined execution and organizational clarity to AppMed’s growing operations.
BL
Brigitte Leonard
SENIOR COMMERCIAL DIRECTOR
Brings broad leadership experience across patient advocacy, healthcare equity, business strategy, and medical affairs. Combines strategic vision with strong stakeholder engagement to support growth, partnerships, and commercial execution at AppMed.
LP
Louis-Paul Marin, Eng., LL.B., LL.M.
FOUNDER & CHAIRMAN OF THE BOARD
Dual-qualified professional with a unique blend of expertise in engineering and law. Brings innovative solutions to the highly regulated field of medical devices — with an in-depth understanding of product design, manufacturing processes, quality assurance, and compliance standards. With a strong commitment to ethical practices and patient safety, Louis-Paul drives innovation in the regulatory landscape, ensuring that life-saving technologies reach those who need them most.
MJ
Marilyne Joly, B.Sc. M.Sc. LLB
CO-FOUNDER & LEGAL COUNSEL
A robust multidisciplinary background combining a pharmacology degree, a master’s degree in biochemistry, and a law degree. Marilyne excels in regulatory affairs for medical devices — mastering the creation, development, and implementation of approval and clearance strategies for medical devices in Canada, the United States, and Europe. Skilled in navigating complex regulatory requirements within quality management frameworks.
GP
Gilles Pelletier, M.Eng., MBA
CO-FOUNDER & CTO
Senior consultant in software verification and validation for medical instruments. Has led teams of 40+ engineers and software scientists, implementing software development processes adhering to regulatory standards across medical devices and Air Traffic Control systems.
JOIN US

Ready to Build the
Future
with AppMed™

Whether you’re a clinician, researcher, institution, or investor, AppMed™ is built for all of you. Let’s bring precision medicine to every step of care, together.

Registre des calculs · Niveaux de risque visibles


Trois niveaux de risque — alignés sur les recommandations CMAJ​

Busse. CMAJ March 18, 2024 196 (10) E327-E340
Faible

MME total quotidien sous le seuil de risque modéré.

Modéré

≥ 50 MME/jour — révision et surveillance accrues.

Élevé

≥ 90 MME/jour — bannière d’avertissement affichée.

Voies orale, transdermique et parentérale prises en charge. Table de conversion modifiable par administrateur.

Pharmacologie non-linéaire — bannière de prudence dédiée plutôt qu’une conversion linéaire trompeuse.

Chaque calcul est tagué avec la version de la table de conversion en vigueur — interprétable même après mise à jour.

Une fois associé à un PSO actif, le calcul devient immuable — la valeur ancrant le sevrage ne peut plus être modifiée.


Quatre étapes pour calculer un MME

The result displays a total daily dose, a color-coded risk level, and, when the 90 MME/day threshold is exceeded, an inline clinical warning.

1- Sélectionner les opioïdes

Une ligne par molécule (orale, transdermique, parentérale).

2- Saisir dose et fréquence

Doses par jour et dose unitaire.

3- Vérifier le total

Niveau de risque chromatique et avertissement le cas échéant.

4- Sauvegarder

Tag horodaté + version de référence pour ancrage au PSO.